The chimeric transcript RUNX1–GLRX5: a biomarker for good postoperative prognosis in Stage IA non-small-cell lung cancer

Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Rie, Amano, Yosuke, Kawakami, Masanori, Sunohara, Mitsuhiro, Watanabe, Kousuke, Kage, Hidenori, Ohishi, Nobuya, Yatomi, Yutaka, Nakajima, Jun, Fukayama, Masashi, Nagase, Takahide, Takai, Daiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731000/
https://www.ncbi.nlm.nih.gov/pubmed/26685324
http://dx.doi.org/10.1093/jjco/hyv187
Descripción
Sumario:Stage IA non-small-cell lung cancer cases have been recognized as having a low risk of relapse; however, occasionally, relapse may occur. To predict clinical outcome in Stage IA non-small-cell lung cancer patients, we searched for chimeric transcripts that can be used as biomarkers and identified a novel chimeric transcript, RUNX1–GLRX5, comprising RUNX1, a transcription factor, and GLRX5. This chimera was detected in approximately half of the investigated Stage IA non-small-cell lung cancer patients (44/104 cases, 42.3%). Although there was no significant difference in the overall survival rate between RUNX1–GLRX5-positive and -negative cases (P = 0.088), a significantly lower relapse rate was observed in the RUNX1–GLRX5-positive cases (P = 0.039), indicating that this chimera can be used as a biomarker for good prognosis in Stage IA patients. Detection of the RUNX1–GLRX5 chimeric transcript may therefore be useful for the determination of a postoperative treatment plan for Stage IA non-small-cell lung cancer patients.

Ejemplares similares